Certara Inc.
| NASDAQ: CERT | Healthcare / Biotechnology / USA |
| 27.53 | -0.5300 | -1.89% | Vol 110.86K | 1Y Perf -27.40% |
| Apr 19th, 2021 12:17 DELAYED |
| BID | 27.43 | ASK | 27.59 | ||
| Open | 27.73 | Previous Close | 28.06 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 36.00 | Analyst Rating | — — 0.00 | |
| Potential % | 30.25 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★ 47.33 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★+ 51.69 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 4.21B | Earnings Rating | — | |
| Price Range Ratio 52W % | 17.14 | Earnings Date | 3rd Jun 2021 |
Today's Price Range 27.3028.42 | 52W Range 24.5841.79 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | 4.08% | ||
| 1 Month | -10.95% | ||
| 3 Months | - | ||
| 6 Months | - | ||
| 1 Year | -27.40% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -7.28 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -4.12 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | 2.12 | |||
Return on invested Capital Q | -4.95 | |||
Return on invested Capital Y | -2.43 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 4.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -71.00 | ||||
| 4.89 | ||||
| 17.12 | ||||
| 78.10 | ||||
| 110.80 | ||||
| 0.34 | ||||
| -43.27 | ||||
| 5.37 | ||||
| 4.05B | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.50 | ||||
| 4.60 | ||||
| 0.26 | ||||
| 0.36 | ||||
| -1.00 | ||||
| Leverage Ratio | 1.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 58.60 | ||||
| 14.20 | ||||
| 32.50 | ||||
| - | ||||
| -20.28 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 243.53M | ||||
| 1.59 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.42 | -0.37 | 11.90 |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 3rd Jun 2021 |
| Estimated EPS Next Report | 0.04 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 110.86K |
| Shares Outstanding | 152.98M |
| Trades Count | 880 |
| Dollar Volume | 11.75M |
| Avg. Volume | 639.52K |
| Avg. Weekly Volume | 206.24K |
| Avg. Monthly Volume | 784.64K |
| Avg. Quarterly Volume | 649.69K |
Certara Inc. (NASDAQ: CERT) stock closed at 28.06 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 291.78K shares and market capitalization of 4.21B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 899 people. Certara Inc. CEO is William F. Feehery.
The one-year performance of Certara Inc. stock is -27.4%, while year-to-date (YTD) performance is %. CERT stock has a five-year performance of %. Its 52-week range is between 24.58 and 41.79, which gives CERT stock a 52-week price range ratio of 17.14%
Certara Inc. currently has a PE ratio of -71.00, a price-to-book (PB) ratio of 4.89, a price-to-sale (PS) ratio of 17.12, a price to cashflow ratio of 78.10, a PEG ratio of 2.32, a ROA of -4.12%, a ROC of 2.12% and a ROE of -7.28%. The company’s profit margin is -20.28%, its EBITDA margin is 32.50%, and its revenue ttm is $243.53 Million , which makes it $1.59 revenue per share.
Of the last four earnings reports from Certara Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.04 for the next earnings report. Certara Inc.’s next earnings report date is 03rd Jun 2021.
The consensus rating of Wall Street analysts for Certara Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Certara Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Certara Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Certara Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 5.22, ATR14 : 1.11, CCI20 : 35.94, Chaikin Money Flow : 0.07, MACD : 0.79, Money Flow Index : 54.43, ROC : 6.29, RSI : 25.24, STOCH (14,3) : 82.70, STOCH RSI : 1.00, UO : 53.59, Williams %R : -17.30), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Certara Inc. in the last 12-months were:
Certara Inc.
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides proven modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines.
CEO: William F. Feehery
Telephone: +1 609 716-7900
Address: 100 Overlook Center, Princeton 08540, NJ, US
Number of employees: 899
